Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis

Abstract

Chronic inflammation and fibrosis are significant factors in the pathogenesis of metabolic-associated fatty liver disease (MAFLD). In this study, we conducted a bibliometric analysis of publications on inflammation and fibrogenesis in MAFLD, with a focus on reporting publication trends. Our findings indicate that the USA and China are the most productive countries in the field, with the University of California San Diego being the most productive institution. Over the past 23 years, Prof. Diehl AM has published 25 articles that significantly contributed to the research community. Notably, the research focus of the field has shifted from morbid obesity and adiponectin to metabolic syndrome, genetics, and microbiome. Our study provides a comprehensive and objective summary of the historical characteristics of research on inflammation and fibrogenesis in MAFLD, which will be of interest to scientific researchers in this field.

Introduction

MAFLD, formerly known as non-alcoholic fatty liver disease (NAFLD), is distinguished by hepatic steatosis and the presence of one or more of the following factors: overweight/obesity, type 2 diabetes mellitus (T2DM), or indications of metabolic dysregulation (1). Strikingly, MAFLD affects approximately a quarter of the population worldwide with a rising trend (2) and involves a spectrum of liver diseases that range from simple steatosis to its progressive form, non-alcoholic steatohepatitis (NASH), characterized by inflammation and progressive tissue fibrosis, and may lead to the development of cirrhosis and even hepatocellular carcinoma (HCC) (2). Moreover, MAFLD aggravates the deteriorative progression of T2DM and its complications (3), and significantly increases the risk of chronic kidney disease (CKD) (4) along with cardiovascular disease (5). Nevertheless, the clinical management of MAFLD is currently restricted to lifestyle interventions with no approved drug therapy for the disease.

It has been widely accepted that chronic inflammation and fibrosis formation play pivotal roles in the pathogenesis of MAFLD (6). In a physiological state, the hepatic inflammatory response is a response to various stress conditions, which is beneficial to repairing tissue damage and promoting hepatic homeostasis (7). However, prolonged or intense inflammatory reactions may result in irreversible liver damage, such as liver fibrosis, which is triggered by the activation of hepatic stellate cells (HSCs) and their transdifferentiation into myofibroblasts (8). According to the “multiple hit” hypothesis, a comprehensive and detailed theory focusing on the pathomechanism of MAFLD, inflammation may precede steatosis in NASH, and inflammatory mechanisms are involved in the entire process of MAFLD (9). Moreover, synergistic effects of pathological events, such as endoplasmic reticulum (ER) stress (10), insulin resistance (11), aberrant lipid metabolism (12), oxidative stress (13), and mitochondrial dysfunction (14), make great contributions to the exacerbation of inflammation and the deterioration of fibrogenesis via various pathways, and have all been implicated in the progression of MAFLD. Therefore, it is meaningful to illustrate and summarize the research trend on inflammation and fibrogenesis in MAFLD with the hope of discovering drug targets and developing effective therapies.

Comparatively to literature reviews, bibliometrics conducts quantitative research on the field’s literature by analyzing its characteristics with the help of visualizing processing tools, like CiteSpace or VOSviewer, to identify the predominant institutions/countries, leading authors and journals, top-cited references, research trend, or hotspots (15). Considering that hepatic inflammation and fibrogenesis are of great importance in the progress of MAFLD, no bibliometric study has been reported on this topic. Therefore, our study aims to identify the publication trends and potentially significant hotspots on inflammation and fibrogenesis in MAFLD by analyzing the records published from 2000 to 2022.

Materials and methods

Data sources and search strategies

In our study, we selected the Web of Science Core Collection Science Citation Index Expanded (WoSCC-SCIE) database for the literature search from 2000 to 2022 on 6 January 2023. All data extraction and downloads were completed on the same day to avoid bias in database updates. The search strategy is as follows: (TS = (inflammation and fibrosis)) AND (TS = (mafld or nafld or ‘‘nonalcoholic fatty liver disease’’ or ‘‘non-alcoholic fatty liver disease’’ or ‘‘metabolic associated fatty liver disease’’ or ‘‘metabolic-associated fatty liver disease’’)), then non-English literature and other types of literature were excluded, and only articles were enrolled in this study. Then, the raw data were downloaded from WoSCC-SCIE as text files involving full records and cited references. A total of 2,348 articles were ultimately analyzed in our study. The detailed flowchart is shown in Figure 1.

Figure 1

Bibliometric analysis

We mainly analyzed the data by VOSviewer (version 1.6.18) and CiteSpace software (version 6.2.R2 advance). The specific method was described before (16). VOSviewer is a software tool for constructing and visualizing bibliometric networks, and is often used to summarize the most prolific countries/regions, institutions, journals, and authors (see www.vosviewer.com). In our study, VOSviewer was used to show the top 10 most cited journals and achievements of different countries/regions and institutions. CiteSpace is another metrological analysis software developed by Prof. Chen C for bibliometric analysis and visualization (17). In this study, CiteSpace was used to evaluate multiple indicators, including the collaboration between countries/regions and authors, co-citation analysis, citation burst, clustered networks of co-cited references, and keywords with the strongest citation bursts.

Results

Quantity and trends analysis of published papers

A total of 2,348 documents were retrieved from the WoSCC-SCIE databases between 2000 and 2022 according to the flowchart shown in Figure 1. As shown in Figure 2, there was an overall upward trend in the amount of literature on inflammation and fibrogenesis in MAFLD, although in some years, the amount of literature could be declining. It is worth noting that 1,412 articles were published in the past 5 years, accounting for 60.14% of the total, implying that MAFLD has become a common chronic disease that has attracted the attention of researchers worldwide.

Figure 2

Productive countries/regions and institutions

To determine which countries or regions have contributed the most to the development of this field during the past 23 years, we counted the number of articles published by different countries and regions using VOSviewer, and the top 10 most productive countries or regions are shown in Table 1. We found that the USA ranked first, followed by China, Japan, Italy, and Germany. Meanwhile, we concluded that the number of publications from the USA and China far exceeded those other countries/regions. In addition, the number of publications in China first surpassed that in the USA in 2021.

At the same time, we analyzed cooperative relationships between these countries and regions via CiteSpace. As shown in Figure 3, the size of the concentric circle is positively related to the number of articles published by each country and region; the fuchsia ring indicates a node with a centrality value greater than 0.1, signifying its close relationship with other nodes. We found that 6 of the top 10 fruitful countries worked closely with others. Among them, China ranked second in terms of the number of published articles, but its international cooperation with other countries needs to be strengthened.

Figure 3

Moreover, we analyzed the contribution of global institutions. The most yielding institutions are shown in Table 1. Interestingly, among the top 10 productive institutions, 7 were from the USA, 2 came from China, and 1 was from Italy. The University of California San Diego published the most articles (74 articles), followed by Duke University (n = 43), Shanghai Jiao Tong University (n = 41), Mayo University (n = 37), and Harvard Medical School (n = 35).

Analysis of journals

Over the past 23 years, 606 scholarly journals have published a total number of 2,348 original articles. We used VOSviewer to show journal influence. The top 10 most cited journals related to the topic of inflammation and fibrogenesis in MAFLD are presented in Table 2. According to the analysis, hepatology publications had the most publications (141 papers) and the most citations (22934) during the past 23 years, followed by those in Gastroenterology (9,737), Journal of Hepatology (6191), Plos One (3,941), and New England Journal of Medicine (3,421). In addition, eight journals were in the Q1 Journal Citation Reports (JCR) division, indicating their high academic standing. Notably, seven of these journals are from the USA, and the remaining three are from the Netherlands and the UK, with all of them being developed countries and therefore providing an important platform for the research development in this field.

Analysis of authors

The top 10 most productive authors in this field are shown in Figure 4A and Table 3. Diehl AM from the Department of Gastroenterology of Duke University published 25 articles in this field and was ranked first, followed by Nobili V, Alisi A, Sanyal AJ, and Feldstein AE. She seemed interested in the connection between the Hedgehog (Hh) pathway and MAFLD (18–20) and carried out an in-depth study in this field. Furthermore, she took part in a clinical research discussing the efficacy of pioglitazone versus vitamin E versus placebo in non-diabetic patients with NASH, showing that vitamin E was a potential treatment well accepted with its high citation rate (21). Furthermore, she discussed the relationship between MAFLD and different reproductive life cycles, such as puberty and menopause (22, 23). The second one was Nobili V, from the Department of Pediatrics of Sapienza university of Rome, who has published 23 articles in this field and made great contributions to the field of children with MAFLD. His most cited article published in Hepatology studied lifestyle intervention and antioxidant therapy in children with MAFLD (24). Several articles suggested that various genetic mutations were associated with MAFLD, such as the PCSK7 gene variation (25) and the I148M patatin-like phospholipase domain-containing 3 gene mutation (26). Interestingly, Alisi A, from the same institution as Nobili V, published 23 articles and was ranked third. Most of her works were cooperated with Dr. Nobili V, showing their close cooperation and strong scientific research ability.

Figure 4

Co-cited authors are those whose works were cited in more than one study at the same time. The network visualization map for the co-cited authors is shown in Figure 4B and Table 3. Kleiner DE ranked first with a total citation of 949 times, followed by Angulo P, Younossi ZM, Brunt EM, and Chalasani N. Among the top 10 most co-cited authors, 3 were the top 10 productive authors, and 4 were the first authors of the most cited articles of derived papers shown in Table 4. In general, the low centrality value indicated a lack of cooperation among them.

Analysis of document citation

Citation analysis is a reliable indicator for assessing the quality of articles, the results were derived from WoSCC-SCIE, and the top 10 most cited articles are shown in Table 4. The article published in Hepatology in 2005 ranked first. It presented a scoring system to assess a large range of histological features of NAFLD for pediatric and adult NAFLD (27). The next one was published in the New England Journal of Medicine in 2010, which was a clinical study discussing the efficacy of pioglitazone and vitamin E for the treatment of NASH in adults without diabetes. It was conducted in cooperation with Diehl AM, who ranked first in the number of published articles (21). The third one also focused on histological features and approved the crucial role of fibrosis stage in managing and monitoring in NAFLD patients (28). Among the top 10 most cited articles, 6 were from Gastroenterology, 2 were from Hepatology, and 2 were from the New England Journal of Medicine. It is worth noting that all of the above three journals were top-cited, enhancing the reliability of the results shown in Table 2.

Analysis of co-cited references and clustered network

Co-cited references are two or more references cited by another paper or more papers simultaneously. From 2000 to 2022, a total of 2,348 articles and their 53,816 references retrieved from WoSCC-SCIE were analyzed by CiteSpace, the first authors of the top 10 most co-cited references are presented in Figure 5A, and the summary of the top 10 most co-cited references is shown in Table 5. Interestingly, it seems to be well-accepted that the fibrosis stage of patients with MAFLD is an independent factor for the long-term outcomes, such as mortality, liver transplantation, and liver-related events (28, 29). In brief, the most cited references shown in Table 5 made great contributions to the development of inflammation and fibrogenesis in the MAFLD scientific community and were the most recognized papers in this field.

Figure 5

In addition, we also analyzed the strong citation burst of references in this topic. The references of the top 20 references with the strongest citation bursts are shown in Figure 6. “Year” refers to the publication date, “Begin” refers to the first citation, and “End” refers to the last citation. We found that the two papers with 4 years’ duration were all focused on seeking effective treatment methods for MAFLD, indicating experts’ concern for this disease (21, 30). The strongest citation reference was a meta-analysis review published by Hepatology in 2016, which is still widely cited and was the top high-cited reference, discussing the epidemiology of NAFLD, including prevalence, incidence, and long-term outcomes (2). Five other pieces of literature still widely cited described the mechanism, diagnosis, treatment, and global burden of MAFLD (31–33).

Figure 6

The map of the co-citation cluster according to keywords generated from the references of 2,348 citing articles by CiteSpace is shown in Figure 5B. The clustering modularity Q and the mean silhouette value were 0.6833 and 0.8729, respectively, demonstrating a credible structure and clustering results. Furthermore, the number of cluster labels is inversely proportional to the number of articles included in each cluster. Thus, the “#0 LPS” cluster contains the most papers, while the “#9 morbid obesity” cluster contains the fewest. The summary of clusters is listed in Table 6.

Analysis of the research trend and burst detection

In order to analyze the change in research hotspots and trends, a timeline view is displayed in Figure 7. We found that early research concentrated on “#8 adiponectin” and “#9 morbid obesity”, interim studies concentrated on “#0 LPS”, “#2 oxidized fatty acids”, and “#6 fatty liver”, whereas current studies concentrated on “#1 metabolic syndrome (MS),” “#3 genetics”, and “#5 microbiome”, indicating changes in research hotspots.

Figure 7

Keyword burst detection is another effective way to explore research hotspots. Figure 8 shows the top 25 keywords with the strongest citation bursts on research from 2000 to 2022. Among the identified keyword bursts, chronic hepatitis C began in 2000 and ended in 2015 with the longest lasting time, which was associated with liver steatosis and was a risk factor for MAFLD. Moreover, three keyword bursts continue to last until the end of 2022, including management, stress, and fibrosis stage.

Figure 8

Discussion

In this bibliometric analysis study, we found 2,348 articles regarding inflammation and fibrogenesis in MAFLD from 2000 to 2022 in the WoSCC-SCIE. With the help of VOSviewer and CiteSpace software, our study analyzed publication trends about inflammation and fibrogenesis in MAFLD from all aspects to shed light on researchers interested in this field.

Between 2000 and 2013, less than 100 articles concerning inflammation and fibrogenesis in MAFLD were published per year globally. However, the number of papers has increased rapidly since 2018, which was associated with the renaming of NAFLD and its high morbidity, indicating that the research on inflammation and fibrogenesis in MAFLD has caught the attention of researchers worldwide. Table 1 shows that the USA played a vital role in the research on inflammation and fibrogenesis in MAFLD. Notably, with the development of China’s medical and scientific research capability, the number of articles published in China has rapidly increased and firstly surpassed the USA in 2021. Moreover, with the development of globalization, international cooperation has become a new trend that benefits the output of high-quality research. The collaborations between countries/regions are shown in Figure 3, most (n = 6) of the top 10 productive countries/regions cooperated closely with other countries, but China greatly needs to strengthen its cooperation with other countries.

Remarkably, 7 of the top 10 productive institutions and 7 of the top 10 most cited journals are from the USA, reasonably explaining that the USA occupies the main contribution on total numbers of published papers. Therefore, these results demonstrated that the USA played a dominant role in the world’s academic activities. However, China may be a rising star in the next few years, considering the number of papers published in this field and its rising trends.

The timeline view in Figure 7 indicates the evolution of the research trend. We found that early research concentrated on adiponectin and morbid obesity. Adiponectin is an adipocyte-specific secretory protein that plays a pivotal role in glycolipid metabolism (34) and extracellular matrix (ECM) metabolism (35) and has made a great contribution to preventing the liver from steatosis, inflammation, and fibrosis (36, 37). It has been reported that MAFLD patients have significantly lower plasma adiponectin levels (38). Multivariate regression analysis identifies decreased adiponectin as an independent risk factor of hepatic steatosis (37). Furthermore, abundant clinical and basic studies have illustrated that adiponectin agonists are therapeutic targets for NAFLD therapy (39, 40). Morbid obesity was defined as a body mass index (BMI) of at least 40 kg/m². Many researchers suggest that Roux-en-Y gastric bypass (RYGB) surgery is a decent curative method in morbid obesity patients with MAFLD to improve inflammation and fibrosis and then inhibit malignant progression to NASH (41–43). Subsequently, interim research mainly focused on identifying novel markers and cellular and molecular mechanisms in MAFLD (44, 45).

With the deepening study in this field, there is increasing evidence to show that MS is an important risk factor in MAFLD, vividly illustrated by the renaming of NAFLD to MAFLD. MS mainly refers to hyperglycemia, abdominal obesity, and dyslipidemia. A systematic review attempted to estimate the prevalence of MAFLD among patients with T2DM and found that the prevalence of MAFLD was 55.5% among 49,419 T2DM patients (46). Another research suggested that more than 90% of obese patients with T2DM also have MAFLD (47), indicating that MAFLD is strongly associated with hyperglycemia. Moreover, studies among T2DM participants have demonstrated that plasma glucose level is positively correlated with the risk of developing advanced liver disease (HCC) (48). Furthermore, glycemic variability, except for hyperinsulinemia and hyperglycemia, is an independent predictive factor for the progression of hepatic fibrosis in MAFLD (49). Considering that there is no approved drug for NASH to date, lifestyle interventions and combinations of drugs, which can effectively regulate glucose and lipid metabolism and reduce liver inflammation and fibrosis, might be a beneficial option to curb the deteriorated progression of MAFLD. Even new drug development focuses on the restitution of metabolic derangements and halting inflammatory and fibrogenic pathways, showing that MS plays an important role in the development of MAFLD (50).

Furthermore, it has been reported that genetic factors took part in the progression of MAFLD due to the upgrading and improvement of new genomic and proteomic technologies (51), and many risk variants of the NAFLD population were identified by a genome-wide association study (GWAS) (52). Currently, at least five variants in different genes are associated with the development and progression of MAFLD, namely, PNPLA3, TM6SF2, GCKR, MBOAT7, and HSD17B13 (53–55). Some of them are associated with an increased risk of T2DM. Others are associated with the risk of developing obesity (56, 57), indicating that MAFLD might have shared mechanisms that are involved in the pathogenesis of T2DM and obesity, emphasizing the importance of MS in MAFLD, and supporting the renaming of NAFLD to MAFLD (55).

Gut microbiota is another research hotspot now. Many studies showed that microbiota might improve or aggravate MAFLD through multiple mechanisms (58–60), including changing the permeability of the intestine (61), altering the expression of genes involved in the de novo lipogenesis (62), and regulating choline (63) and bile acid metabolism (64). The most extensively studied microbial molecule is lipopolysaccharide (LPS), which is produced by Gram-negative bacteria. It has been reported that systemic LPS concentration was significantly elevated in rats treated with HFD and high-sucrose diet (65) and in MAFLD patients (66). In related animal studies, the effect of LPS on the development of MAFLD has also been shown in mice injected with LPS and mice lacking toll-like receptor 4 (TLR4) (67, 68). A number of studies investigated that modulation of the gut microbiota may be a potential therapeutic target for MAFLD, including using antibiotics, prebiotics, and probiotics (69).

Generally speaking, Figure 7 demonstrates that the research hotspots have shifted their direction to MS, genetics, and the microbiome in the study of inflammation and fibrosis in MAFLD.

Another effective method of reflecting the transition of hotspots in an academic area is to use keyword bursts. The top 25 keywords with the strongest citation bursts are shown in Figure 8. Among them, three keywords continue to last by the end of 2022. The first one is management. The related research with the highest citation was published in Hepatology in 2019, elucidating that gut microbiota profile and systemic inflammatory response in NAFLD were closely related, further promoting the process of HCC (70). Some of the works concerned the relationship between MAFLD and common chronic diseases (71, 72), and most publications explored effective methods to curb the development of MAFLD and its complications (73–76). The second one was fibrosis stage, a valuable parameter to predict all-cause and liver disease-related mortality in MAFLD (77). The related articles mainly focused on seeking potential ways to restrain the adverse progression of fibrosis stage and thus improve the prognosis (78–80). For example, Khurana and Wang attempted to find an invasive method that is helpful for early diagnosis, distinguishing disease staging, and giving personalized treatments (81, 82). The third keyword burst, which started in 2019, was stress. Articles related to this keyword refer to a metabolic stress state relevant to the dysfunction of mitochondria and ER and describe its potential mechanisms that have a significant impact on the progress of MAFLD. Zhang et al. suggested that impaired mitophagy, which may lead to the accumulation of excessive ROS production and oxidative stress, triggered hepatic NLRP3 inflammasome activation during the progress of MAFLD (83). In addition, another research noted that down-regulating the NLRP3/NF-κB signaling pathway can attenuate inflammation in mouse liver (84). Meanwhile, the authors identified apoptosis signal-regulating kinase 1 (ASK1) as a suppressor of NASH and fibrosis formation via ASK1 knockout experiments. All of them reminded us that inflammation and fibrosis are key factors in the development of MAFLD and drugs that act on them may have potential as a clinical treatment to prevent MAFLD in humans.

Of note, magnetic resonance elastography (MRE), a keyword that lasted from 2017 to 2019, is a non-invasive evaluation to distinguish healthy people from those with NAFLD and assess the degree of fibrosis to discriminate simple steatosis from NASH (85), showing that colleagues are actively looking for non-invasive methods to determine the severity of NAFLD, and thus ensure timely and optimal treatment.

Notably, the number of publications focusing on inflammation and fibrosis in MAFLD increased rapidly. However, previous studies on inflammation and fibrogenesis in MAFLD still have certain limitations, and there is much to be improved in the future.

• 1. It is urgent to identify more valuable non-invasive biomarkers to meet the need to accurately stage the progression of MAFLD, make a definitive diagnosis as soon as possible, and provide the patients with timely and effective treatment.

• 2. More research on developing novel agents targeting hepatic inflammation and fibrosis are needed as there are no approved drugs for NASH.

• 3. There are numerous basic studies, but few can be applied to the clinic. The use of non-human primate models rather than rodents in mechanistic investigations would likely allow for a higher chance of translating basic discoveries into clinical practice.

Our study has some limitations. First, we only analyzed data exported from WoSCC-SCIE to undertake relevant analysis, which may result in selection bias. Second, this study excluded non-English literature, and some high-quality non-English literature was excluded. Third, VOSviewer and CiteSpace have certain defects that may output discredited results. Nevertheless, our study still provides significant information and insights for researchers interested in this field.

Conclusion

From 2000 to 2022, the number of articles focusing on inflammation and fibrosis in MAFLD increased rapidly, especially in the last 5 years. The USA played a vital role in the development of this topic regarding the number of publications, international cooperation with other countries, and achievements of authors. However, China may be a rising star in this research field with its increasing trend in the number of publications and its huge population. Current research mainly focuses on MS, genetics, and microbiome. Considering the urgent and emergent situation of inflammation and fibrosis in MAFLD, more studies are needed to focus on developing novel drugs and identifying non-invasive biomarkers. In short, our study provides a comprehensive overview of this discipline, which could more precisely direct scholars in future research and provide valuable guidance for clinical diagnosis, appropriate treatment, and individualized prevention.

References

• 1

  EslamMNewsomePNSarinSKAnsteeQMTargherGRomero-GomezMet al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol (2020) 73(1):202–9. doi: 10.1016/j.jhep.2020.03.039

  • CrossRef
  • Google Scholar

• 2

  YounossiZMKoenigABAbdelatifDFazelYHenryLWymerM. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology (2016) 64(1):73–84. doi: 10.1002/hep.28431

  • CrossRef
  • Google Scholar

• 3

  MantovaniAScorlettiEMoscaAAlisiAByrneCDTargherG. Complications, morbidity and mortality of nonalcoholic fatty liver diseasme. Metab - Clin Exp (2020) 111S:154170. doi: 10.1016/j.metabol.2020.154170

  • CrossRef
  • Google Scholar

• 4

  SuWChenMXiaoLDuSXueLFengRet al. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. Front Public Health (2022) 10:1047794. doi: 10.3389/fpubh.2022.1047794

  • CrossRef
  • Google Scholar

• 5

  AnsteeQMMantovaniATilgHTargherG. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2018) 15(7):425–39. doi: 10.1038/s41575-018-0010-0

  • CrossRef
  • Google Scholar

• 6

  FriedmanSLNeuschwander-TetriBARinellaMSanyalAJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med (2018) 24(7):908–22. doi: 10.1038/s41591-018-0104-9

  • CrossRef
  • Google Scholar

• 7

  KubesPMehalWZ. Sterile inflammation in the liver. Gastroenterology. (2012) 143(5):1158–72. doi: 10.1053/j.gastro.2012.09.008

  • CrossRef
  • Google Scholar

• 8

  TsuchidaTFriedmanSL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 14(7):397–411. doi: 10.1038/nrgastro.2017.38

  • CrossRef
  • Google Scholar

• 9

  TilgHMoschenAR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology (2010) 52(5):1836–46. doi: 10.1002/hep.24001

  • CrossRef
  • Google Scholar

• 10

  FlessaC-MKyrouINasiri-AnsariNKaltsasGKassiERandevaHS. Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD). J Cell Biochem (2022) 123(10):1585–606. doi: 10.1002/jcb.30247

  • CrossRef
  • Google Scholar

• 11

  SakuraiYKubotaNYamauchiTKadowakiT. Role of insulin resistance in MAFLD. Int J Mol Sci (2021) 22(8):4156. doi: 10.3390/ijms22084156

  • CrossRef
  • Google Scholar

• 12

  GengYFaberKNde MeijerVEBlokzijlHMoshageH. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int (2021) 15(1):21–35. doi: 10.1007/s12072-020-10121-2

  • CrossRef
  • Google Scholar

• 13

  ClareKDillonJFBrennanPN. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepatol (2022) 10(5):939–46. doi: 10.14218/JCTH.2022.00067

  • CrossRef
  • Google Scholar

• 14

  PirolaCJGianottiTFBurgueñoALRey-FunesMLoidlCFMallardiPet al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. (2013) 62(9):1356–63. doi: 10.1136/gutjnl-2012-302962

  • CrossRef
  • Google Scholar

• 15

  ChenC. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA (2004) 101(Suppl 1):5303–10. doi: 10.1073/pnas.0307513100

  • CrossRef
  • Google Scholar

• 16

  PeiZChenSDingLLiuJCuiXLiFet al. Current perspectives and trend of nanomedicine in cancer: A review and bibliometric analysis. J Control Release. (2022) 352:211–41. doi: 10.1016/j.jconrel.2022.10.023

  • CrossRef
  • Google Scholar

• 17

  ChenCSongI-YYuanXZhangJ. The thematic and citation landscape of Data and Knowledge Engineering (1985–2007). Data Knowledge Engineering. (2008) 67(2):234–59. doi: 10.1016/j.datak.2008.05.004

  • CrossRef
  • Google Scholar

• 18

  SundaramSSSwiderska-SynMSokolRJHalbowerACCapocelliKEPanZet al. Nocturnal hypoxia activation of the hedgehog signaling pathway affects pediatric nonalcoholic fatty liver disease severity. Hepatol Commun (2019) 3(7):883–93. doi: 10.1002/hep4.1354

  • CrossRef
  • Google Scholar

• 19

  Swiderska-SynMSuzukiAGuyCDSchwimmerJBAbdelmalekMFLavineJEet al. Hedgehog pathway and pediatric nonalcoholic fatty liver disease. Hepatology (2013) 57(5):1814–25. doi: 10.1002/hep.26230

  • CrossRef
  • Google Scholar

• 20

  GuyCDSuzukiAZdanowiczMAbdelmalekMFBurchetteJUnalpAet al. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology (2012) 55(6):1711–21. doi: 10.1002/hep.25559

  • CrossRef
  • Google Scholar

• 21

  SanyalAJChalasaniNKowdleyKVMcCulloughADiehlAMBassNMet al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 362(18):1675–85. doi: 10.1056/NEJMoa0907929

  • CrossRef
  • Google Scholar

• 22

  SuzukiAAbdelmalekMFSchwimmerJBLavineJEScheimannAOUnalp-AridaAet al. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 10(7):786–94. doi: 10.1016/j.cgh.2012.01.020

  • CrossRef
  • Google Scholar

• 23

  YangJDAbdelmalekMFGuyCDGillRMLavineJEYatesKet al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2017) 15(1):127–31.e2. doi: 10.1016/j.cgh.2016.07.034

  • CrossRef
  • Google Scholar

• 24

  NobiliVMancoMDevitoRDi CiommoVComparcolaDSartorelliMRet al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology (2008) 48(1):119–28. doi: 10.1002/hep.22336

  • CrossRef
  • Google Scholar

• 25

  DongiovanniPMeroniMBaselliGMancinaRMRuscicaMLongoMet al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res (2019) 60(6):1144–53. doi: 10.1194/jlr.P090449

  • CrossRef
  • Google Scholar

• 26

  ValentiLAlisiAGalmozziEBartuliADel MenicoBAlterioAet al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology (2010) 52(4):1274–80. doi: 10.1002/hep.23823

  • CrossRef
  • Google Scholar

• 27

  KleinerDEBruntEMVan NattaMBehlingCContosMJCummingsOWet al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 41(6):1313–21. doi: 10.1002/hep.20701

  • CrossRef
  • Google Scholar

• 28

  AnguloPKleinerDEDam-LarsenSAdamsLABjornssonESCharatcharoenwitthayaPet al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Hepatology (2015) 149(2):389–97.e10. doi: 10.1053/j.gastro.2015.04.043

  • CrossRef
  • Google Scholar

• 29

  EkstedtMHagströmHNasrPFredriksonMStålPKechagiasSet al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatol (Baltimore Md). (2015) 61(5):1547–54. doi: 10.1002/hep.27368

  • CrossRef
  • Google Scholar

• 30

  Neuschwander-TetriBALoombaRSanyalAJLavineJEVan NattaMLAbdelmalekMFet al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (2015) 385(9972):956–65. doi: 10.1016/S0140-6736(14)61933-4

  • CrossRef
  • Google Scholar

• 31

  ChalasaniNYounossiZLavineJECharltonMCusiKRinellaMet al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (2018) 67(1):328–57. doi: 10.1002/hep.29367

  • CrossRef
  • Google Scholar

• 32

  BuzzettiEPinzaniMTsochatzisEA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab - Clin Experimental. (2016) 65(8):1038–48. doi: 10.1016/j.metabol.2015.12.012

  • CrossRef
  • Google Scholar

• 33

  YounossiZAnsteeQMMariettiMHardyTHenryLEslamMet al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatology. (2018) 15(1):11–20. doi: 10.1038/nrgastro.2017.109

  • CrossRef
  • Google Scholar

• 34

  TaoCSifuentesAHollandWL. Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes. Best Pract Res Clin Endocrinol Metab (2014) 28(1):43–58. doi: 10.1016/j.beem.2013.11.003

  • CrossRef
  • Google Scholar

• 35

  ZhaoCWuMZengNXiongMHuWLvWet al. Cancer-associated adipocytes: emerging supporters in breast cancer. J Exp Clin Cancer Res (2020) 39(1):156. doi: 10.1186/s13046-020-01666-z

  • CrossRef
  • Google Scholar

• 36

  HeydariMCornide-PetronioMEJiménez-CastroMBPeraltaC. Data on adiponectin from 2010 to 2020: therapeutic target and prognostic factor for liver diseases? Int J Mol Sci (2020) 21(15):5242. doi: 10.3390/ijms21155242

  • CrossRef
  • Google Scholar

• 37

  TargherGBertoliniLScalaLPoliFZenariLFalezzaG. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf). (2004) 61(6):700–3. doi: 10.1111/j.1365-2265.2004.02151.x

  • CrossRef
  • Google Scholar

• 38

  PaganoCSoardoGEspositoWFalloFBasanLDonniniDet al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinology. (2005) 152(1):113–8. doi: 10.1530/eje.1.01821

  • CrossRef
  • Google Scholar

• 39

  GastaldelliAHarrisonSBelfort-AguiarRHardiesJBalasBSchenkerSet al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther (2010) 32(6):769–75. doi: 10.1111/j.1365-2036.2010.04405.x

  • CrossRef
  • Google Scholar

• 40

  AlzahraniBIseliTRamezani-MoghadamMHoVWankellMSunEJet al. The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochim Biophys Acta Mol basis disease. (2018) 1864(3):700–8. doi: 10.1016/j.bbadis.2017.12.012

  • CrossRef
  • Google Scholar

• 41

  de AlmeidaSRSavassi RochaPRDias SanchesMRios LeiteVHda SilvaRAPCosta DinizMTet al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surgery. (2006) 16(3):270–8. doi: 10.1381/096089206776116462

  • CrossRef
  • Google Scholar

• 42

  FuruyaCKJr.De OliveiraCPMSDe MelloESFaintuchJRaskovskiAMatsudaMet al. Effects of bariatric surgery on nonalcoholic fatty liver disease: Preliminary findings after 2 years. J Gastroenterol Hepatol (2007) 22(4):510–4. doi: 10.1111/j.1440-1746.2007.04833.x

  • CrossRef
  • Google Scholar

• 43

  KleinSMittendorferBEagonJCPattersonBGrantLFeirtNet al. Gastric bypass surgery improves metabolic and hepatic abnorMalities associated with nonalcoholic fatty liver disease. Gastroenterology. (2006) 130(6):1564–72. doi: 10.1053/j.gastro.2006.01.042

  • CrossRef
  • Google Scholar

• 44

  FeldsteinAELopezRTamimiTA-RYerianLChungY-MBerkMet al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [S]. J Lipid Res (2010) 51(10):3046–54. doi: 10.1194/jlr.M007096

  • CrossRef
  • Google Scholar

• 45

  SubramanianSGoodspeedLWangSKimJZengLIoannouGNet al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res (2011) 52(9):1626–35. doi: 10.1194/jlr.M016246

  • CrossRef
  • Google Scholar

• 46

  YounossiZMGolabiPde AvilaLPaikJMSrishordMFukuiNet al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol (2019) 71(4):793–801. doi: 10.1016/j.jhep.2019.06.021

  • CrossRef
  • Google Scholar

• 47

  TolmanKGFonsecaVDalpiazATanMH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care (2007) 30(3):734–43. doi: 10.2337/dc06-1539

  • CrossRef
  • Google Scholar

• 48

  PangYKartsonakiCTurnbullIGuoYClarkeRChenYet al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: A prospective study of 0.5 million people. Hepatol (Baltimore Md) (2018) 68(4):1308–18. doi: 10.1002/hep.30083

  • CrossRef
  • Google Scholar

• 49

  HashibaMOnoMHyogoHIkedaYMasudaKYoshiokaRet al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PloS One (2013) 8(11):e76161. doi: 10.1371/journal.pone.0076161

  • CrossRef
  • Google Scholar

• 50

  RojasÁLara-RomeroCMuñoz-HernándezRGatoSAmpueroJRomero-GómezM. Emerging pharmacological treatment options for MAFLD. Ther Adv Endocrinol Metab (2022) 13:20420188221142452. doi: 10.1177/20420188221142452

  • CrossRef
  • Google Scholar

• 51

  SuppliMPRigboltKTGVeidalSSHeebøllSEriksenPLDemantMet al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am J Physiol Gastrointest Liver Physiol (2019) 316(4):G462–G72. doi: 10.1152/ajpgi.00358.2018

  • CrossRef
  • Google Scholar

• 52

  EslamMValentiLRomeoS. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol (2018) 68(2):268–79. doi: 10.1016/j.jhep.2017.09.003

  • CrossRef
  • Google Scholar

• 53

  Abul-HusnNSChengXLiAHXinYSchurmannCStevisPet al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med (2018) 378(12):1096–106. doi: 10.1056/NEJMoa1712191

  • CrossRef
  • Google Scholar

• 54

  KozlitinaJSmagrisEStenderSNordestgaardBGZhouHHTybjærg-HansenAet al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2014) 46(4):352–6. doi: 10.1038/ng.2901

  • CrossRef
  • Google Scholar

• 55

  CarlssonBLindénDBrolénGLiljebladMBjursellMRomeoSet al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2020) 51(12):1305–20. doi: 10.1111/apt.15738

  • CrossRef
  • Google Scholar

• 56

  MahajanAWesselJWillemsSMZhaoWRobertsonNRChuAYet al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet (2018) 50(4):559–71. doi: 10.1038/s41588-018-0084-1

  • CrossRef
  • Google Scholar

• 57

  Perez-Diaz-Del-CampoNAbeteICanteroIMarin-AlejandreBAMonrealJIElorzMet al. Association of the SH2B1 rs7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease. Nutrients. (2020) 12(5):1260. doi: 10.3390/nu12051260

  • CrossRef
  • Google Scholar

• 58

  BoursierJMuellerOBarretMMaChadoMFizanneLAraujo-PerezFet al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatol (Baltimore Md). (2016) 63(3):764–75. doi: 10.1002/hep.28356

  • CrossRef
  • Google Scholar

• 59

  MichailSLinMFreyMRFanterRPaliyOHilbushBet al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol (2015) 91(2):1–9. doi: 10.1093/femsec/fiu002

  • CrossRef
  • Google Scholar

• 60

  ImSTMunHParkSKangHKimWCHeoS-Jet al. Ishige okamurae Celluclast extract ameliorates non-alcoholic fatty liver in high-fructose diet-fed mice by modulation of lipid metabolism and gut microbiota composition. Food Chem Toxicol (2023) 177:113864. doi: 10.1016/j.fct.2023.113864

  • CrossRef
  • Google Scholar

• 61

  LutherJGarberJJKhaliliHDaveMBaleSSJindalRet al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol (2015) 1(2):222–32. doi: 10.1016/j.jcmgh.2015.01.001

  • CrossRef
  • Google Scholar

• 62

  KangHYouHJLeeGLeeSHYooTChoiMet al. Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. Gut Microbes (2022) 14(1):2078612. doi: 10.1080/19490976.2022.2078612

  • CrossRef
  • Google Scholar

• 63

  ChenYMLiuYZhouRFChenXLWangCTanXYet al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep (2016) 6:19076. doi: 10.1038/srep19076

  • CrossRef
  • Google Scholar

• 64

  ArabJPKarpenSJDawsonPAArreseMTraunerM. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology (2017) 65(1):350–62. doi: 10.1002/hep.28709

  • CrossRef
  • Google Scholar

• 65

  ZhouXHanDXuRLiSWuHQuCet al. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet. PloS One (2014) 9(12):e115148. doi: 10.1371/journal.pone.0115148

  • CrossRef
  • Google Scholar

• 66

  SharifniaTAntounJVerriereTGCSuarezGWattacherilJWilsonKTet al. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol (2015) 309(4):G270–G8. doi: 10.1152/ajpgi.00304.2014

  • CrossRef
  • Google Scholar

• 67

  CaniPDAmarJIglesiasMAPoggiMKnaufCBastelicaDet al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. (2007) 56(7):1761–72. doi: 10.2337/db06-1491

  • CrossRef
  • Google Scholar

• 68

  SprussAKanuriGWagnerbergerSHaubSBischoffSCBergheimI. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatol (Baltimore Md). (2009) 50(4):1094–104. doi: 10.1002/hep.23122

  • CrossRef
  • Google Scholar

• 69

  MaJZhouQLiH. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy. Nutrients. (2017) 9(10):1124. doi: 10.3390/nu9101124

  • CrossRef
  • Google Scholar

• 70

  PonzianiFRBhooriSCastelliCPutignaniLRivoltiniLDel ChiericoFet al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology (2019) 69(1):107–20. doi: 10.1002/hep.30036

  • CrossRef
  • Google Scholar

• 71

  ViglinoDJullian-DesayesIMinovesMAron-WisnewskyJLeroyVZarskiJ-Pet al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J (2017) 49(6):1601923. doi: 10.1183/13993003.01923-2016

  • CrossRef
  • Google Scholar

• 72

  MonteilletLGjorgjievaMSilvaMVerzieuxVImikireneLDuchamptAet al. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Mol Metab (2018) 16:100–15. doi: 10.1016/j.molmet.2018.07.006

  • CrossRef
  • Google Scholar

• 73

  ChalasaniNAbdelmalekMFGarcia-TsaoGVuppalanchiRAlkhouriNRinellaMet al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. (2020) 158(5):1334–45.e5. doi: 10.1053/j.gastro.2019.11.296

  • CrossRef
  • Google Scholar

• 74

  LeeSMKohDHJunDWRohYJKangHTOhJHet al. Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways. Clin Mol Hepatol (2022) 28(4):827–40. doi: 10.3350/cmh.2022.0068

  • CrossRef
  • Google Scholar

• 75

  WangCDuanXSunXLiuZSunPYangXet al. Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice. Food Funct (2016) 7(9):3716–23. doi: 10.1039/C6FO00773B

  • CrossRef
  • Google Scholar

• 76

  NakashimaASugimotoRSuzukiKShirakataYHashiguchiTYoshidaCet al. Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis. Food Sci Nutr (2019) 7(1):139–47. doi: 10.1002/fsn3.828

  • CrossRef
  • Google Scholar

• 77

  HagströmHNasrPEkstedtMHammarUStålPHultcrantzRet al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol (2017) 67(6):1265–73. doi: 10.1016/j.jhep.2017.07.027

  • CrossRef
  • Google Scholar

• 78

  AkutaNKawamuraYFujiyamaSSezakiHHosakaTKobayashiMet al. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology. Internal Med (2020) 59(16):1931–7. doi: 10.2169/internalmedicine.4398-19

  • CrossRef
  • Google Scholar

• 79

  LoombaRLawitzEMantryPSJayakumarSCaldwellSHArnoldHet al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology (2018) 67(2):549–59. doi: 10.1002/hep.29514

  • CrossRef
  • Google Scholar

• 80

  HuberYBoyleMHallsworthKTiniakosDStraubBKLabenzCet al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol (2019) 17(10):2085–92.e1. doi: 10.1016/j.cgh.2018.12.016

  • CrossRef
  • Google Scholar

• 81

  KhuranaSButtWKharaHSJohalASWestSFChenZ-MEet al. Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis. Hepatol Int (2019) 13(3):323–9. doi: 10.1007/s12072-019-09945-4

  • CrossRef
  • Google Scholar

• 82

  WangZ-HZhengKIWangX-DQiaoJLiY-YZhangLet al. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreatic Dis Int (2021) 20(5):452–9. doi: 10.1016/j.hbpd.2021.05.008

  • CrossRef
  • Google Scholar

• 83

  ZhangN-PLiuX-JXieLShenX-ZWuJ. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. Lab Invest (2019) 99(6):749–63. doi: 10.1038/s41374-018-0177-6

  • CrossRef
  • Google Scholar

• 84

  WangQOuYHuGWenCYueSChenCet al. Naringenin attenuates nonalcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice. Br J Pharmacol (2020) 177(8):1806–21. doi: 10.1111/bph.14938

  • CrossRef
  • Google Scholar

• 85

  Costa-SilvaLFerollaSMLimaASVidigalPVTFerrariTCDA. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiology (2018) 98:82–9. doi: 10.1016/j.ejrad.2017.11.003

  • CrossRef
  • Google Scholar